<DOC>
	<DOCNO>NCT01193335</DOCNO>
	<brief_summary>The purpose study describe safety , tolerability , immunogenicity 2,3,4 12 month schedule 13-valent pneumococcal conjugate vaccine give preterm infant concomitant vaccine , compare infant bear term.There follow-up phase ass persistence antibody response 24 36 month age .</brief_summary>
	<brief_title>Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Preterm Compared Term Infants .</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy Infants 42 98 day age ( approximately 2 month ) time enrollment . Previous vaccination pneumococcal vaccine , Haemophilus influenzae type B ( Hib ) conjugate vaccine , meningococcal type C conjugate vaccine , diphtheria , tetanus , pertussis , poliovirus vaccine . Previous anaphylactic reaction allergy vaccine Contraindication vaccination Known suspect immune deficiency immune suppression Major know congenital malformation serious chronic disorder Significant neurological disorder Participation another study</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>13-valent pneumococcal conjugate vaccine</keyword>
	<keyword>premature</keyword>
	<keyword>immunization</keyword>
	<keyword>safety .</keyword>
</DOC>